Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | SYK | P43405 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.53 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 2/20 | 0.50 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.49 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7771269 | 0.90 | EGFR (0.66) | TP53MAPTHDAC6SYKCYP3A4 | |
| SCHEMBL657571 | 0.88 | TP53 (0.62) | TP53MAPTHDAC6SYKCYP3A4 | |
| SCHEMBL16250487 | 0.88 | TP53 (0.62) | TP53MAPTHDAC6SYKCYP3A4 | |
| SCHEMBL21704805 | 0.84 | TP53 (1.00) | TP53MAPTHDAC6SYKCYP3A4 | |
| SCHEMBL658048 | 0.82 | SYK (0.60) | TP53MAPTHDAC6SYKCYP3A4 | |
| SCHEMBL12517646 | 0.82 | TNNI3K (0.85) | EGFRTNNI3K | |
| SCHEMBL16234786 | 0.81 | TP53 (0.54) | TP53MAPTHDAC6SYKCYP3A4 | |
| SCHEMBL1317961 | 0.80 | HDAC6 (1.00) | TP53MAPTHDAC6SYKCYP3A4 | |
| SCHEMBL16250488 | 0.80 | MAPT (0.50) | TP53MAPTHDAC6SYKEGFR | |
| SCHEMBL657020 | 0.79 | SYK (0.72) | TP53MAPTHDAC6SYKCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286809-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2009-11-19 | — | — | US | claimed |
| EP-1473289-B1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | BTG INT LTD (GB) | 2009-08-05 | — | — | EP | claimed |
| US-20080182846-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LIMITED (GB) | 2008-07-31 | — | — | US | claimed |
| US-20050054732-A1 | Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds | BTG INTERNATIONAL LTD. (GB) | 2005-03-10 | — | — | US | claimed |
| EP-1473289-A1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | Sankyo Company, Limited (JP) | 2004-11-03 | — | — | EP | claimed |
| US-20110275640-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | disclosed |
| US-8003645-B2 | type II diabetes; 6-Ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine; suppress the fall in MTT reduction capacity by beta -amyloid protein; inhibit impairment of long-term potentiation of hippocampal nerve cells, pyrimidine or 1,3,5 triazine derivatives | BTG INTERNATIONAL LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20090286794-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286809-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2009-11-19 | — | — | US | disclosed |
| US-7589105-B2 | For example, N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine, 2-methyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine | BTG INTERNATIONAL LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1473289-B1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | BTG INT LTD (GB) | 2009-08-05 | — | — | EP | disclosed |
| US-20080182846-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LIMITED (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20050054732-A1 | Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds | BTG INTERNATIONAL LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| EP-1473289-A1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | Sankyo Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054732-A1 | Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds | NAT1, APP, BACE1 | TP53 3057/4885MAPT 115/4885HDAC6 666/4885 |
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | TP53 1526/4885MAPT 13/4885HDAC6 664/4885 |
| US-20090286794-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | TP53 1526/4885MAPT 13/4885HDAC6 664/4885 |
| US-20090286809-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | TP53 1526/4885MAPT 13/4885HDAC6 664/4885 |
| US-20080182846-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | TP53 1526/4885MAPT 13/4885HDAC6 664/4885 |
| US-20110275640-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | TP53 1526/4885MAPT 13/4885HDAC6 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.